Related Experiment Video
Updated: Mar 26, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.9K
Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for
Stefano Christian Londero1, Marie Louise Jespersen2, Annelise Krogdahl3
1Department of ENT Head and Neck Surgery, Odense University Hospital, Odense, Denmark Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark stefano.londero@rsyd.dk.
Anticancer Research
|February 7, 2016
Summary
A 17-gene classifier was developed to predict metastatic potential in papillary thyroid carcinoma. However, validation showed it lacked prognostic significance for recurrence, indicating a need for better biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Papillary thyroid carcinoma (PTC) lacks reliable biomarkers for metastatic potential.
- Accurate risk stratification is crucial for effective PTC patient management.
Purpose of the Study:
- To develop a gene-expression classifier to predict metastatic potential in papillary thyroid carcinoma.
- To evaluate the classifier's prognostic significance for recurrence.
Main Methods:
- Genome-wide expression analyses were performed on two cohorts: a development cohort (n=38) and a validation cohort (n=183).
- A 17-gene classifier was identified based on expression data from the development cohort.
- The classifier's performance was tested against clinical data in the validation cohort.
Main Results:
- A 17-gene classifier differentiating metastatic from non-metastatic PTC was identified.
- The classifier demonstrated 51.5% sensitivity and 61.6% specificity for detecting metastases in the validation cohort.
- Log-rank testing revealed no significant prognostic value for recurrence (p=0.32).
Conclusions:
- A 17-gene classifier reflecting biological differences related to metastatic potential in PTC was developed.
- Despite initial identification, the classifier did not prove to be a significant prognostic marker for recurrence in validation.
- Further research is needed to identify reliable biomarkers for PTC metastatic potential.
